Amgen Joins China Oncology Market Race With $2.7bn BeiGene Stake

 
• By Brian Yang

As China embraces novel new drugs, oncology is quickly becoming the biggest opportunity for pharma to drive growth in this market. Amgen is the latest to jump on board through the purchase of a significant stake in BeiGene.

China
AMGEN INVESTS $2.7bn IN BEIJING-BASED BEIGENE TO SEIZE CHINA ONCOLOGY MARKET OPPORTUNITIES • Source: Shutterstock

More from China

More from Focus On Asia